Marinus Pharmaceuticals Inc. announced the Unites States commercial launch of Ztalmy oral suspension for the treatment of seizures associated with CDKL5 deficiency disorder in patients aged 2 years and older.
According to a company press release, Ztalmy (ganaxolone, Marinus) is the first and only FDA-approved treatment specifically indicated for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD) in patients as young as 2 years.
The drug — a sugar-free, cherry-flavored oral suspension administered three times per day — is a neuroactive steroid